Company Overview and News

2
ASX closes higher on gold miners

2018-10-03 theage.com.au
Australian shares closed the session higher, ending a poor start to the week's trading, as the major material stocks led the market gains.
NCMGF NCM RIO BLT RIO EVN SCEXF NST IGO RSG RTPPF RMGGF RTNTF IOOFY SBM CAHPF FMG MS BHPBF IFL IIDDY FSUGY NESRF IOOFF NCMGY FSUMF RMGGY BHP RIO BBL BHP NHRNY BHPLF SAR

2
ASX closes higher on gold miners

2018-10-03 watoday.com.au
Australian shares closed the session higher, ending a poor start to the week's trading, as the major material stocks led the market gains.
NCMGF NCM RIO BLT RIO EVN SCEXF NST IGO RSG RTPPF RMGGF RTNTF IOOFY SBM CAHPF FMG MS BHPBF IFL IIDDY FSUGY NESRF IOOFF NCMGY FSUMF RMGGY BHP RIO BBL BHP NHRNY BHPLF SAR

2
ASX closes higher on gold miners

2018-10-03 smh.com.au
Australian shares closed the session higher, ending a poor start to the week's trading, as the major material stocks led the market gains.
NCMGF NCM RIO BLT RIO EVN SCEXF NST IGO RSG RTPPF RMGGF RTNTF IOOFY SBM CAHPF FMG MS BHPBF IFL IIDDY FSUGY NESRF IOOFF NCMGY FSUMF RMGGY BHP RIO BBL BHP NHRNY BHPLF SAR

 
Big Australian fund manager divests Commonwealth Bank over misconduct

2018-09-05 channelnewsasia
SYDNEY: Wealth manager Perpetual Ltd said it has divested Commonwealth Bank of Australia from its AU$1.3 billion (US$933.6 million) ethical fund due to revelations of corporate misconduct, the first big institutional investor to do so.
NAUBF WBC IOOFF WBC IFL NAB NASXF IOOFY WEBNF NABZY WBK

 
Exclusive: Big Australian fund manager divests Commonwealth Bank over misconduct

2018-09-05 reuters
SYDNEY (Reuters) - Wealth manager Perpetual Ltd (PPT.AX) said it has divested Commonwealth Bank of Australia (CBA.AX) from its A$1.3 billion ($933.6 million) ethical fund due to revelations of corporate misconduct, the first big institutional investor to do so.
NAUBF WBC IOOFF WBC IFL NAB NASXF IOOFY WEBNF NABZY WBK

 
NAB, CBA recommended for criminal charges in commission findings

2018-08-24 theage.com.au
National Australia Bank and the Commonwealth Bank could face possible criminal charges over legal breaches in their superannuation arms following recommendations by the royal commission.
NAUBF IOOFF NAB NASXF IFL IOOFY NABZY

 
NAB, CBA recommended for criminal charges in commission findings

2018-08-24 smh.com.au
National Australia Bank and the Commonwealth Bank could face possible criminal charges over legal breaches in their superannuation arms following recommendations by the royal commission.
NAUBF IOOFF NAB NASXF IFL IOOFY NABZY

12
Deals of the day-Mergers and acquisitions

2018-07-26 reuters
July 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Thursday: ** Qualcomm Inc walked away from a $44 billion deal to buy NXP Semiconductors after failing to secure Chinese regulatory approval, becoming a high profile victim of a bitter Sino-U.S. trade spat.
REG MZTSY IFL ARNC AFLYY MZTLF AFRAF IOOFF IOOFY QCOM

14
How a powerful inquiry upended one of Australia's grandest companies

2018-06-22 theedgemarkets
SYDNEY (June 22): One of Australia's oldest financial institutions, AMP Ltd, spent years building the country's largest network of financial advisers to recommend its products, and well over a century polishing its brand.
ARG MQBKY IFL AMP AGVNF MCQEF IOOFF IOOFY MS MQG

1
Clayton office fetches $24.6m from IOOF Holdings Limited

2018-05-25 theage.com.au
The first investment grade office to hit the market this year has sold to IOOF Holdings Limited for $24.6 million – some $2 million above expectation.
PMV IOOFF IFL IOOFY JLL

1
Clayton office fetches $24.6m from IOOF Holdings Limited

2018-05-25 smh.com.au
The first investment grade office to hit the market this year has sold to IOOF Holdings Limited for $24.6 million – some $2 million above expectation.
PMV IOOFF IFL IOOFY JLL

9
Australia’s ANZ cuts financial planner bonuses as inquiry reshapes an industry

2018-05-07 thestar.com.my
SYDNEY: Australia’s ANZ said it would quit paying bonuses to financial planners for selling its products, becoming the country’s first major lender to change business practices in response to a powerful inquiry that has unmasked widespread misconduct in the sector. The move by Australia and New Zealand Banking Group Ltd highlights how the Royal Commission has started to refashion an industry central to the world’s 12th largest economy, just three months into what is scheduled to be a year-long run.
NAUBF WBC IOOFF WBC IFL AMP NAB NASXF IOOFY WEBNF NABZY WBK

9
Australia's ANZ cuts financial planner bonuses as inquiry reshapes an industry

2018-05-07 reuters
SYDNEY (Reuters) - Australia’s ANZ said it would quit paying bonuses to financial planners for selling its products, becoming the country’s first major lender to change business practices in response to a powerful inquiry that has unmasked widespread misconduct in the sector.
NAUBF WBC IOOFF WBC IFL AMP NAB NASXF IOOFY WEBNF NABZY WBK

2
‘Golden Period’ of Australian Banking Over, ANZ Bank Chief Says - Bloomberg

2018-05-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ZURVY IOOFF IFL IOOFY ZFSVF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:IFL / IOOF HOLDINGS LIMITED on message board site Silicon Investor.

IFLB - Infinium Labs, Inc. IFLB - Infinium Labs, Inc. IFLB - Infinium Labs, Inc. IFLO Corporation IFLO Corporation IFLO Corporation
IFLY - travel sales on the web pure play IFLY - travel sales on the web pure play IFLY - travel sales on the web pure play NIFL Nova International Films NIFL Nova International Films NIFL Nova International Films
VIFL VIFL VIFL IFLO is Breaking Out IFLO is Breaking Out IFLO is Breaking Out
AFFT BREAKING OUT--THE NEXT IFLY AFFT BREAKING OUT--THE NEXT IFLY AFFT BREAKING OUT--THE NEXT IFLY IFLY - A civil approach IFLY - A civil approach IFLY - A civil approach
I am long IFLY go ahead and short it I am long IFLY go ahead and short it I am long IFLY go ahead and short it THE NEXT IFLY--TRIP THE NEXT IFLY--TRIP THE NEXT IFLY--TRIP